Shinya Takasaki

Shinya Takasaki

Auto-generated profile, based on publicly available information

Shinya Takasaki

Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Miyagi 980-8574, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
TSTomonori Sato
Tomonori Sato
YKYoshihide Kawasaki
Yoshihide Kawasaki
MMMasamitsu Maekawa
Masamitsu Maekawa
STShinya Takasaki
Shinya Takasaki
KMKento Morozumi
Kento Morozumi
AIAkihiro Ito
Akihiro Ito
Metabolomics analysis possibly identifies new therapeutic targets in treatment resistance by measuring changes in metabolites accompanying cancer progression. We previously conducted a global metabolomics (G-Met) study of renal cell carcinoma (RCC) and identified metabolites that may be involved in sunitinib resistance in RCC. Here, we aimed to elucidate possible mechanisms of sunitinib resistance in RCC through intracellular metabolites. We established sunitinib-resistant and control RCC cell lines from tumor tissues of RCC cell (786-O)-injected mice. We also quantified characteristic metabolites identified in our G-Met study to compare intracellular metabolism between the two cell lines using liquid chromatography-mass spectrometry. The established sunitinib-resistant RCC cell line demonstrated significantly desuppressed protein kinase B (Akt) and mesenchymal-to-epithelial transition (MET) phosphorylation compared with the control RCC cell line under sunitinib exposure. Among identified metabolites, glutamine, glutamic acid, and α-KG (involved in glutamine uptake into the tricarboxylic acid (TCA) cycle for energy metabolism); fructose 6-phosphate, D-sedoheptulose 7-phosphate, and glucose 1-phosphate (involved in increased glycolysis and its intermediate metabolites); and glutathione and myoinositol (antioxidant effects) were significantly increased in the sunitinib-resistant RCC cell line. Particularly, glutamine transporter (SLC1A5) expression was significantly increased in sunitinib-resistant RCC cells compared with control cells. In this study, we demonstrated energy metabolism with glutamine uptake and glycolysis upregulation, as well as antioxidant activity, was also associated with sunitinib resistance in RCC cells.


18 February 2021 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
TSToshihiro Sato
Toshihiro Sato
MSMasato Suzuka
Masato Suzuka
YSYuji Sato
Yuji Sato
RIRiko Iwabuchi
Riko Iwabuchi
DKDaisuke Kobayashi
Daisuke Kobayashi
NMNariyasu Mano
Nariyasu Mano

12 March 2019 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
STShinya Takasaki
Shinya Takasaki
HYHiroaki Yamaguchi
Hiroaki Yamaguchi
YKYoshihide Kawasaki
Yoshihide Kawasaki
MKMasafumi Kikuchi
Masafumi Kikuchi
MTMasaki Tanaka
Masaki Tanaka
NMNariyasu Mano
Nariyasu Mano
Everolimus is an oral inhibitor of mammalian target of rapamycin, approved for metastatic renal cell carcinoma (mRCC). Recently, personalized medicine through therapeutic drug monitoring (TDM) is recommended in cancer therapy. In this study, the relationship between everolimus blood concentration and clinical outcomes on a long-term were evaluated in Japanese patients with mRCC. Patients with mRCC were enrolled following treatment with everolimus at Tohoku University Hospital between April 2012 and December 2016. The relationship between everolimus trough blood concentration on day 8 of everolimus therapy and just before discontinuation or dose reduction, and their adverse events were evaluated. Patients were divided into two groups based on the median of everolimus blood concentration on day 8 of treatment, and the profiles of adverse events, and efficacy [time to treatment failure (TTF) and progression-free survival (PFS)] were evaluated. The median (range) everolimus blood concentrations on day 8 after starting everolimus administration and just before discontinuation or dose reduction were 15.3 (8.1–28.0) ng/mL and 14.8 (6.4–58.4) ng/mL, respectively, with no significant difference between these values (P = 0.3594). Patients (n = 6) with discontinuation or dose reduction following adverse events in everolimus therapy had significantly higher blood concentrations than patients (n = 4) with dose maintenance on both day 8 (median, 18.0 vs 8.2 ng/mL; P = 0.0139) and just before discontinuation or dose reduction (median, 22.9 vs 9.7 ng/mL; P = 0.0142). Median TTF and PFS of the total patients (n = 10) were 96 days (95% confidence interval [CI], 26–288) and 235 days (95% CI, 28–291), respectively. Subgroup analysis showed that TTF of the patients with > 15.3 ng/mL (n = 5) was not significantly different from that of the patients with ≤15.3 ng/mL (n = 5; P = 0.5622). Similarly, PFS of the patients with > 15.3 ng/mL was not significantly different from that of the patients with ≤15.3 ng/mL (P = 0.3436). This study demonstrated the long-term relationship between everolimus blood level and clinical outcomes and adverse events in Japanese patients with mRCC. Thus, TDM in everolimus therapy could be a useful tool for the early prediction of adverse events for Japanese patients with mRCC.

19 March 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
KMKento Morozumi
Kento Morozumi
YKYoshihide Kawasaki
Yoshihide Kawasaki
TSTomonori Sato
Tomonori Sato
MMMasamitsu Maekawa
Masamitsu Maekawa
STShinya Takasaki
Shinya Takasaki
AIAkihiro Ito
Akihiro Ito
Tyrosine kinase inhibitors (TKIs) play a crucial role in the treatment of advanced renal cell carcinoma (RCC). However, there is a lack of useful biomarkers for assessing treatment efficacy. Through urinary metabolite analysis, we identified the metabolites and pathways involved in TKI resistance and elucidated the mechanism of TKI resistance. To verify the involvement of the identified metabolites obtained from urine metabolite analysis, we established sunitinib-resistant RCC cells and elucidated the antitumor effects of controlling the identified metabolic pathways in sunitinib-resistant RCC cells. Through the analysis of VEGFR signaling, we aimed to explore the mechanisms underlying the antitumor effects of metabolic control. Glutamine metabolism has emerged as a significant pathway in urinary metabolite analyses. In vitro and in vivo studies have revealed the antitumor effects of sunitinib-resistant RCC cells via knockdown of glutamine transporters. Furthermore, this antitumor effect is mediated by the control of VEGFR signaling via PTEN. Our findings highlight the involvement of glutamine metabolism in the prognosis and sunitinib resistance in patients with advanced RCC. Additionally, the regulating glutamine metabolism resulted in antitumor effects through sunitinib re-sensitivity in sunitinib-resistant RCC. Our results are expected to contribute to the more effective utilization of TKIs with further improvements in prognosis through current drug therapies.

15 January 2021 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
STShinya Takasaki
Shinya Takasaki
THTensei Hirasawa
Tensei Hirasawa
YSYu Sato
Yu Sato
MMMasamitsu Maekawa
Masamitsu Maekawa
TTTaku Tsukamoto
Taku Tsukamoto
NMNariyasu Mano
Nariyasu Mano